Following our recent acquisition of Gripeo.com website, please direct all inquiry emails to [email protected] and avoid using any other channels to contact website admin and moderators. Thank you so much!

Matthew Eitner: Is He a Fraudster? Uncover The Truth! (2024)

0L0n MQ9zbS0m6Uargv 0rnELjtIGu1pVJOJPM tCgGM7yIEiWrnAoQ55NGSIEkIXlOb0p5HqKuSzKKuOaN8

US Federal Court Issues Temporary Restraining Order Against Laidlaw & Company, Matthew Eitner, and James Ahern

According to the announcement by the court, pertains to a clinical-stage business engaged in the development of new treatments for the treatment of chronic pain. It has been reported that the U.S. District Court for the District of Nevada has issued an Order to prohibit Laidlaw & Company Ltd. and its principals, Matthew Eitner and James Ahern, compared to further dissemination of substitute content that is deemed to be incorrect and deceptive. 

This statement pertains to a legal case in which Relmada already initiated a lawsuit against Laidlaw and individuals Messrs. Eitner & Ahern. The action was based on allegations that Laidlaw provided, as part of their efforts to obtain substantial influence over Relmada. 

Laidlaw, a financial services firm specializing in industrial brokerage costs, has previously fulfilled the role of an investment banker for Relmada. Nevertheless, it is worth noting that Laidlaw including its leaders has a documented track record of non-compliance with U.S. financial regulations, leading to many client grievances, administrative reprimands, and monetary sanctions.

Sergio Traversa, the CEO of Relmada, expressed satisfaction with the judge’s choice to approve our motion and grant the aforementioned order. Our primary objective is to allocate our time and money toward the advancement of Relmada’s range of products, particularly BuTab, which has lately exhibited promising outcomes in clinical studies. 

Nevertheless, we hold the view that granting Laidlaw substantial authority over the Company is not consistent with the optimal welfare of our shareholders. 

Engaging in such measures would have a detrimental impact, as demonstrated by the negative outcomes associated with our transition to NASDAQ as a result of the acts taken by Laidlaw’s leaders, Mr. Matthew Eitner and Mr. Ahern, along with their previously chosen director, Dr. Nabil Yazgi. These details may be seen in our news statement. 

It is a belief that Laidlaw’s rights diverge significantly from those of the remaining Relmada owners. Consequently, we are committed to undertaking all necessary measures to safeguard the Company including the common goals of all Relmada investors. 

According to the Court’s ruling, it was determined that Relmada has a high probability of achieving success in its legal claim due to the presence of significant inaccuracies and errors in the False Solicitation. 

Additionally, the Court recognized that both Relmada as well as the shareholders of the company would experience severe and irreversible damage if Laidlaw along with its principals i.e. Matthew Eitner were not prohibited from further distributing deceptive proxy materials and compelled to rectify or amend said materials. 

Consequently, the Order has been duly issued and is scheduled to lapse. The different litigants shall convene for a scheduled session by the Court on that same date. The Regulation is going to be made accessible by the submission of Form 8-K to the Securities and Exchange Commission (SEC).

Our Methodology

We look at 34 different data points when analyzing and rating online money-earning opportunities. Once the research on these data points is submitted, expert contributors reach out to the company’s customers and associates to get more insight into their operation. Finally, all the collected information is presented in the form of this expert review.

All the data is extracted from publicly available information and the sources are given in the transparency section at the bottom of every report.

These reports are made possible by the collective efforts of contributors like you. If you would like to become a contributor then contact us here.

Matthew Eitner: Accused of Fraud Case

According to the BrokerCheck document retrieved on June 20, 2023, Matthew Eitner, an authorized stockbroker affiliated with Laidlaw & Company, was implicated in a shareholder complaint. If you want to know more about his disclosure, you may learn from the link: Matthew Eitner

Disclosure: Matthew Eitner 

Allegations

A customer complaint has named Matthew D. Eitner.

Damage

$57,375.43

BrokerCheck report of Matthew Eitner.

Matthew Eitner: Disputes Among Investors

It was reported that on April 28, 2023, an investor named Matthew Eitner filed a complaint against Laidlaw & Company, accusing them of fraud, misrepresentation, negligence, charging excessive commissions, and causing a loss of opportunity. 

As a result of an arbitration award, Matthew Eitner was held jointly and severally liable for $57,375.43 in damages along with the other respondents.

FINRA Rule 2010 

Brokers must adhere to high standards of commercial honor and principles of just and equitable trade under FINRA Rule 2010.

FINRA Rule 2020

The utilization of deceptive tactics, manipulative techniques, and other forms of deceptive behavior to exert influence on the sale and purchase of securities is strictly prohibited by FINRA Rule 2020. 

Engaging in misrepresentation or omission of important details, such as a stock’s future earnings, hazards, or additional pertinent variables, constitutes a violation of this regulation.

FINRA Rule 2111 

According to FINRA Rule 2111, brokers are obligated to consider the financial objectives of clients while providing recommendations for potential investments. To ensure compliance with regulatory requirements as well as effectively manage investment portfolios, brokers are obligated to engage in a thorough consultation process with investors. 

This process involves a careful examination of the investor’s profile, which encompasses crucial aspects such as their tax status, risk tolerance, as well as other relevant data.

Investments may also exhibit statistical unsuitability. The occurrence of a high volume of transactions might result in the imposition of trading costs and commissions, which have the potential to significantly diminish clients’ profits to the extent that the trader fails to yield any profit.

Clients who depend on brokerage for investment guidance can seek recourse through FINRA adjudication to get back their losses in money.

Matthew Eitner: What Constitutes Broker Negligence?

Broker negligence like Matthew Eitner did can take on many forms, including unsuitable investment recommendations, misrepresentations or omissions of material facts, and excessive trading. If you have suffered financial losses as a result of broker negligence, you may have the option to recover your funds by pursuing FINRA arbitration.

Matthew Eitner: Background Details 

Matthew Eitner has completed the following examinations:

Series 63 – Uniform Securities Agent State Law Examination

Series 79TO – Investment Banking Registered Representative Examination

Series 57TO – Securities Trader Exam

Series 99TO – Operations Professional Examination and many more. 

Matthew Eitner, despite his association with esteemed organizations, became embroiled in a fraudulent incident, earning the label of a fraudster.

What is Kurta Law?

Xtb5qWu2U9AZJ2h9 MQpj1pwVKQozJA10Zs2PEfK85YXkmmWnGeja3FrG8JyltlXIiTaqWf YilFPZtn9kzFfWRl qcsWu0Morij YJT3h6GgdVsgb M Hq4qz24GJH40hVnfDn7z5ZeGnkuNaeoq0

If you have collaborated with Matthew Eitner & possess apprehensions regarding your financial future, we kindly request that you reach out to us promptly for a complimentary discussion. You may contact us at 877-600-0098 or via email at in**@ku**********.com.

Kurta Law has been engaged in the advocacy of clients seeking to recuperate their financial losses against brokers & brokerage companies for more than two decades. 

Kurta Law is a law practice of national repute that specializes in providing legal representation to investors in their pursuit of claims involving brokerage and brokerage companies. 

The company operates on a contingency fee schedule, wherein legal fees are contingent upon the successful outcome of the case. This implies that the company solely receives compensation if our legal professionals specializing in equities successfully get monetary restitution on your behalf.

About Matthew Eitner 

vPGewv

Matthew Eitner serves as the Chief Executive Officer (CEO) of Laidlaw & Company UK Inc., a prominent financial institution specializing in investment banking and wealth advisory services. 

He takes an active role in providing support to many charitable organizations and assumes positions on multiple boards. Matt completed his undergraduate studies in Business Management at the College of Scranton in Pennsylvania. 

Subsequently, he embarked on his professional journey as a stocks trader with NDB Capital Markets after graduation. During the early 2000s, he assumed the role of vice president at Casimir Capital & served as the Managing Director at Aegis Capital Corp. 

Matthew Eitner commenced employment at Laidlaw & Co. in the year 2010 and expeditiously ascended to the esteemed role of Chief Executive Officer within a year, specifically in 2011. The individual in question has played a crucial role in strategically establishing the company’s presence within the healthcare industry. 

Additionally, they hold the responsibility of overseeing a team consisting of more than 150 skilled experts, who are geographically dispersed across locations located in both the United States & the United Kingdom. 

The individual in question has gained recognition for his outstanding aptitude in management as well as talent acquisition, resulting in notable advancements regarding organizational growth and team development. 

Under the direction of Matthew Eitner, Laidlaw & Company completed the acquisition of Naples Wealth Planning. Naples Wealth Planning, an independent consulting company valued at $359 million, was included in Laidlaw & Co’s portfolio.

Final Thoughts 

In conclusion, Relmada Therapeutics has taken a significant step in its legal battle against Laidlaw & Company Ltd. and its principals, Matthew Eitner and James Ahern. The U.S. District Court for the District of Nevada has issued a temporary restraining order and an associated injunction to prevent the spread of false and misleading proxy materials. This marks a significant development in the ongoing dispute between the two companies.

We will be happy to hear your thoughts

Leave a reply

Gripeo
Logo
Register New Account